Phytochemical regulation of UDP-glucuronosyltransferases: Implications for cancer prevention

Nutrition and Cancer

Volumn 59, Issue 2, 2007, Pages 121-141

  Saracino, Misty R ^a   Lampe, Johanna W ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; AROMATIC HYDROCARBON; BAICALEIN; BETA CAROTENE; BLACK TEA EXTRACT; CHLOROPHYLL; COUMARIN; CURCUMIN; ELLAGIC ACID; FERULIC ACID; FLAVANONE; FLAVONE; GENISTEIN; GLUCURONOSYLTRANSFERASE; GREEN TEA EXTRACT; HERBACEOUS AGENT; LIMONENE; PREGNANE X RECEPTOR; QUERCETIN; RESVERATROL; RETINOIC ACID; RETINOL; ROSMARINUS OFFICINALIS EXTRACT; SOYBEAN PROTEIN; SULFORAPHANE; TANGERETIN; TRANSCRIPTION FACTOR NRF2; TURMERIC; UNINDEXED DRUG; WOGONIN;

BIOTRANSFORMATION; BROCCOLI; BRUSSELS SPROUT; CANCER CELL CULTURE; CANCER PREVENTION; CANCER RISK; CASSIA SIAMERA; CONCENTRATION RESPONSE; DANDELION; DIET; DIET THERAPY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME REGULATION; GARLIC; HUMAN; LEPIDIUM SATIVUM; NEOPLASM; NONHUMAN; PHYTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; ROSEMARY; SENNA; SIGNAL TRANSDUCTION; TEA; TRANSCRIPTION REGULATION; WATERCRESS;

RODENTIA;

EID: 36849028688     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701458178     Document Type: Review

References (339)

1. Rushmore TH and Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3, 481-490, 2002.
2. Sugatani J, Nishitani S, Yamakawa K, Yoshinari K, Sueyoshi T, et al.: Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol Pharmacol 67, 845-855, 2005.
3. Zhou J, Zhang J, and Xie W: Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases. Curr Drug Metab 6, 289-298, 2005.
4. Brierley CH, Senafi SB, Clarke D, Hsu MH, Johnson EF, et al.: Regulation of the human bilirubin UDP-glucuronosyltransferase gene. Adv Enzyme Regul 36, 85-97, 1996.
5. Gregory PA, Lewinsky RH, Gardner-Stephen DA, and Mackenzie PI: Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 199, 354-363, 2004.
6. Owens IS, Basu NK, and Banerjee R: UDP-glucuronosyltransferases: gene structures of UGT1 and UGT2 families. Methods Enzymol 400, 1-22, 2005.
7. Gong QH, Cho JW, Huang T, Potter C, Gholami N, et al.: Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 11, 357-368, 2001.
8. Tukey RH and Strassburg CP: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40, 581-616, 2000.
9. Mackenzie PI, Walter Bock K, Burchell B, Guillemette C, Ikushiro S, et al.: Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15, 677-685, 2005.
10. Nagar S and Remmel RP: Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25, 1659-1672, 2006.
11. Moon YJ, Wang X, and Morris ME: Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 20, 187-210, 2006.
12. Strassburg CP, Manns MP, and Tukey RH: Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 57, 2979-2985, 1997.
13. Guillemette C, Belanger A, and Lepine J: Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Res 6, 246-254, 2004.
14. Peters U, Sinha R, Bell DA, Rothman N, Grant DJ, et al.: Urinary mutagenesis and fried red meat intake: influence of cooking temperature, phenotype, and genotype of metabolizing enzymes in a controlled feeding study. Environ Mol Mutagen 43, 53-74, 2004.
15. Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, Gregory PA, et al.: Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab Dispos 32, 281-290, 2004.
16. Hu Z and Wells PG: In vitro and in vivo biotransformation and covalent binding of benzo(a)pyrene in Gunn and RHA rats with a genetic deficiency in bilirubin uridine diphosphate-glucuronosyltransferase. J Pharmacol Exp Ther 263, 334-342, 1992.
17. Hu Z and Wells PG: Modulation of benzo[a]pyrene bioactivation by glucuronidation in lymphocytes and hepatic microsomes from rats with a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. Toxicol Appl Pharmacol 127, 306-313, 1994.
18. Berges R, Siess MH, Arnault I, Auger J, Kahane R, et al.: Comparison of the chemopreventive efficacies of garlic powders with different alliin contents against aflatoxin B1 carcinogenicity in rats. Carcinogenesis 25, 1953-1959, 2004.
19. Pantuck EJ, Hsiao KC, Loub WD, Wattenberg LW, Kuntzman R, et al.: Stimulatory effect of vegetables on intestinal drug metabolism in the rat. J Pharmacol Exp Ther 198, 278-283, 1976.
20. Pantuck EJ, Pantuck CB, Garland WA, Min BH, Wattenberg LW, et al.: Stimulatory effect of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 25, 88-95, 1979.
21. Uotila P and Aitio A: The effects of dietary vegetables on rat intestinal and hepatic metabolism of xenobiotics. Res Commun Chem Pathol Pharmacol 26, 425-428, 1979.
22. Pantuck EJ, Pantuck CB, Anderson KE, Wattenberg LW, Conney AH, et al.: Effect of brussels sprouts and cabbage on drug conjugation. Clin Pharmacol Ther 35, 161-169, 1984.
23. Hecht SS, Cannella SG, and Murphy SE: Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol Biomarkers Prev 8, 907-913, 1999.
24. Hecht SS, Chung FL, Richie JP Jr., Akerkar SA, Borukhova A, et al.: Effects of watercress consumption on metabolism of a tobacco-specific lung carcinogen in smokers. Cancer Epidemiol Biomarkers Prev 4, 877-884, 1995.
25. Brennan P, Hsu CC, Moullan N, Szeszenia-Dabrowska N, Lissowska J, et al.: Effect of cruciferous vegetables on lung cancer in patients stratified by genetic status: a mendelian randomisation approach. Lancet 366, 1558-1560, 2005.
26. Le Marchand L, Hankin JH, Kolonel LN, Beecher GR, Wilkens L R, et al.: Intake of specific carotenoids and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2, 183-187, 1993.
27. Swanson CA, Mao BL, Li JY, Lubin JH, Yao SX, et al.: Dietary determinants of lung-cancer risk: results from a case-control study in Yunnan Province, China. Int J Cancer 50, 876-880, 1992.
28. Wang LI, Giovannucci EL, Hunter D, Neuberg D, Su L et al.: Dietary intake of Cruciferous vegetables, Glutathione S-transferase (GST) polymorphisms and lung cancer risk in a caucasian population. Cancer Causes Control 15, 977-985, 2004.
29. Lee AH, Fraser ML, and Binns CW: Possible role for green tea in ovarian cancer prevention. Future Oncol 1, 771-777, 2005.
30. McKay DL and Blumberg JB: The role of tea in human health: an update. J Am Coll Nutr 21, 1-13, 2002.
31. Sun CL, Yuan JM, Koh WP, and Yu MC: Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis 27, 1310-1315, 2006.
32. Sun CL, Yuan JM, Koh WP, and Yu MC: Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 27, 1301-1309, 2006.
33. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768-780, 2003.
34. Talalay P: Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 12, 5-11, 2000.
35. Bianchini F and Vainio H: Isothiocyanates in cancer prevention. Drug Metab Rev 36, 655-667, 2004.
36. Conaway CC, Yang YM, and Chung FL: Isothiocyanates as cancer chemopreventive agents: their biological activities and metabolism in rodents and humans. Curr Drug Metab 3, 233-255, 2002.
37. Keum YS, Jeong WS, and Kong AN: Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat Res 555, 191-202, 2004.
38. Zhang Y: Cancer-preventive isothiocyanates: measurement of human exposure and mechanism of action. Mutat Res 555, 173-190, 2004.
39. Dingley KH, Ubick EA, Chiarappa-Zucca ML, Nowell S, Abel S, et al.: Effect of dietary constituents with chemopreventive potential on adduct formation of a low dose of the heterocyclic amines PhIP and IQ and phase II hepatic enzymes. Nutr Cancer 46, 212-221, 2003.
40. Guo D, Schut HA, Davis CD, Snyderwine EG, Bailey GS, et al.: Protection by chlorophyllin and indole-3-carbinol against 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP)-induced DNA adducts and colonic aberrant crypts in the F344 rat. Carcinogenesis 16, 2931-2937, 1995.
41. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, et al.: Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62, 5196-5203, 2002.
42. Xu M, Bailey AC, Hernaez JF, Taoka CR, Schut HA, et al.: Protection by green tea, black tea, and indole-3-carbinol against 2-amino-3-methylimidazo[4,5- f]quinoline-induced DNA adducts and colonic aberrant crypts in the F344 rat. Carcinogenesis 17, 1429-1434, 1996.
43. Guyonnet D, Siess MH, Le Bon AM, and Suschetet M: Modulation of phase II enzymes by organosulfur compounds from allium vegetables in rat tissues. Toxicol Appl Pharmacol 154, 50-58, 1999.
44. Haber D, Siess MH, Canivenc-Lavier MC, Le Bon AM, and Suschetet M: Differential effects of dietary diallyl sulfide and diallyl disulfide on rat intestinal and hepatic drug-metabolizing enzymes. J Toxicol Environ Health 44, 423-434, 1995.
45. Haber D, Siess MH, de Waziers I, Beaune P, and Suschetet M: Modification of hepatic drug-metabolizing enzymes in rat fed naturally occurring allyl sulphides. Xenobiotica 24, 169-182, 1994.
46. Siess MH, Le Bon AM, Canivenc-Lavier MC, and Suschetet M: Modification of hepatic drug-metabolizing enzymes in rats treated with alkyl sulfides. Cancer Lett 120, 195-201, 1997.
47. Maliakal PP and Wanwimolruk S: Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol 53, 1323-1329, 2001.
48. Nikaidou S, Ishizuka M, Maeda Y, Hara Y, Kazusaka A, et al.: Effect of components of green tea extracts, caffeine and catechins on hepatic drug metabolizing enzyme activities and mutagenic transformation of carcinogens. Jpn J Vet Res 52, 185-192, 2005.
49. Bu-Abbas A, Clifford MN, Ioannides C, and Walker R: Stimulation of rat hepatic UDP-glucuronosyl transferase activity following treatment with green tea. Food Chem Toxicol 33, 27-30, 1995.
50. Bu-Abbas A, Clifford MN, Walker R, and Ioannides C: Contribution of caffeine and flavanols in the induction of hepatic Phase II activities by green tea. Food Chem Toxicol 36, 617-621, 1998.
51. Embola CW, Sohn OS, Fiala ES, and Weisburger JH: Induction of UDP-glucuronosyltransferase 1 (UDP-GT1) gene complex by green tea in male F344 rats. Food Chem Toxicol 40, 841-844, 2002.
52. Santana-Rios G, Orner GA, Xu M, Izquierdo-Pulido M, and Dashwood RH: Inhibition by white tea of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine- induced colonic aberrant crypts in the F344 rat. Nutr Cancer 41, 98-103, 2001.
53. Sohn OS, Surace A, Fiala ES, Richie JP Jr., Colosimo S, et al.: Effects of green and black tea on hepatic xenobiotic metabolizing systems in the male F344 rat. Xenobiotica 24, 119-127, 1994.
54. Sugatani J, Yamakawa K, Tonda E, Nishitani S, Yoshinari K, et al.: The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem Pharmacol 67, 989-1000, 2004.
55. Yang XY, Zhao WP, Li YQ, Sun ZY, Zhang Y, et al.: The role of NF-E2-related factor 2 in the induction of uridine 5′-diphosphate- glucuronosyltransferase 1A and its isoforms by epigallocatechin gallate in colon cancer cells. Zhonghua Yi Xue Za Zhi 86, 82-87, 2006.
56. Chrungoo VJ, Reen RK, Singh K, and Singh J: Effects of silymarin on UDP-glucuronic acid and glucuronidation activity in the rat isolated hepatocytes and liver in relation to D-galactosamine toxicity. Indian J Exp Biol 35, 256-263, 1997.
57. D'Andrea V, Perez LM, and Sanchez Pozzi EJ: Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin- glucuronide. Life Sci 77, 683-692, 2005.
58. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, et al.: Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 28, 1270-1273, 2000.
59. Ueng YF, Shyu CC, Lin YL, Park SS, Liao JF, et al.: Effects of baicalein and wogonin on drug-metabolizing enzymes in C57BL/6J mice. Life Sci 67, 2189-2200, 2000.
60. Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, et al.: Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 30, 1266-1273, 2002.
61. Brouard C, Siess MH, Vernevaut MF, and Suschetet M: Comparison of the effects of feeding quercetin or flavone on hepatic and intestinal drug-metabolizing enzymes of the rat. Food Chem Toxicol 26, 99-103, 1988.
62. Canivenc-Lavier MC, Vernevaut MF, Totis M, Siess MH, Magdalou J, et al.: Comparative effects of flavonoids and model inducers on drug-metabolizing enzymes in rat liver. Toxicology 114, 19-27, 1996.
63. Siess MH, Le Bon AM, and Suschetet M: Dietary modification of drug-metabolizing enzyme activities: dose-response effect of flavonoids. J Toxicol Environ Health 35, 141-152, 1992.
64. van der Logt EM, Roelofs HM, Nagengast FM and Peters WH: Induction of rat hepatic and intestinal UDP-glucuronosyltransferases by naturally occurring dietary anticarcinogens. Carcinogenesis 24, 1651-1656, 2003.
65. Galijatovic A, Otake Y, Walle UK, and Walle T: Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells-potential role in carcinogen bioinactivation. Pharm Res 18, 374-379, 2001.
66. Galijatovic A, Walle UK, and Walle T: Induction of UDP- glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm Res 17, 21-26, 2000.
67. Walle T, Otake Y, Galijatovic A, Ritter JK, and Walle UK: Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab Dispos 28, 1077-1082, 2000.
68. Walle UK and Walle T: Induction of human UDP-glucuronosyltransferase UGT1A1 by flavonoids-structural requirements. Drug Metab Dispos 30, 564-569, 2002.
69. Chen C and Kong AN: Dietary cancer-chemopreventive compounds: from signaling and gene expression to pharmacological effects. Trends Pharmacol Sci 26, 318-326, 2005.
70. Lampe JW: Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr 133(Suppl 3), 956S-964S, 2003.
71. Appelt LC and Reicks MM: Soy induces phase II enzymes but does not inhibit dimethylbenz[a]anthracene-induced carcinogenesis in female rats. J Nutr 129, 1820-1826, 1999.
72. Sun XY, Plouzek CA, Henry JP, Wang TT, and Phang JM: Increased UDP-glucuronosyltransferase activity and decreased prostate specific antigen production by biochanin A in prostate cancer cells. Cancer Res 58, 2379-2384, 1998.
73. Pfeiffer E, Treiling CR, Hoehle SI, and Metzler M: Isoflavones modulate the glucuronidation of estradiol in human liver microsomes. Carcinogenesis 26, 2172-2178, 2005.
74. Basu NK, Ciotti M, Hwang MS, Kole L, Mitra PS, et al.: Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem 279, 1429-1441, 2004.
75. Basu NK, Kole L, Kubota S, and Owens IS: Human UDP- glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 32, 768-773, 2004.
76. Basu NK, Kole L, and Owens IS: Evidence for phosphorylation requirement for human bilirubin UDP-glucuronosyltransferase (UGT1A1) activity. Biochem Biophys Res Commun 303, 98-104, 2003.
77. Goud VK, Polasa K, and Krishnaswamy K: Effect of turmeric on xenobiotic metabolising enzymes. Plant Foods Hum Nutr 44, 87-92, 1993.
78. Naganuma M, Saruwatari A, Okamura S, and Tamura H: Turmeric and curcumin modulate the conjugation of 1-naphthol in Caco-2 cells. Biol Pharm Bull 29, 1476-1479, 2006.
79. Yueh MF and Tukey RH: Nrf2-Keap1 Signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice. J Biol Chem 282, 8749-8758, 2007.
80. Janosek J, Hilscherova K, Blaha L, and Holoubek I: Environmental xenobiotics and nuclear receptors-interactions, effects and in vitro assessment. Toxicol In Vitro 20, 18-37, 2006.
81. Kohle C and Bock KW: Activation of coupled Ah receptor and Nrf2 gene batteries by dietary phytochemicals in relation to chemoprevention. Biochem Pharmacol 72, 795-805, 2006.
82. Quadri SA, Qadri AN, Hahn ME, Mann KK, and Sherr DH: The bioflavonoid galangin blocks aryl hydrocarbon receptor activation and polycyclic aromatic hydrocarbon-induced pre-B cell apoptosis. Mol Pharmacol 58, 515-525, 2000.
83. Auyeung DJ, Kessler FK, and Ritter JK: Mechanism of rat UDP-glucuronosyltransferase 1A6 induction by oltipraz: evidence for a contribution of the Aryl hydrocarbon receptor pathway. Mol Pharmacol 63, 119-127, 2003.
84. Munzel PA, Lehmkoster T, Brack M, Ritter JK, and Bock KW: Aryl hydrocarbon receptor-inducible or constitutive expression of human UDP glucuronosyltransferase UGT1A6. Arch Biochem Biophys 350, 72-78, 1998.
85. Nishimura N, Yonemoto J, Miyabara Y, Fujii-Kuriyama Y, and Tohyama C: Altered thyroxin and retinoid metabolic response to 2,3,7,8-tetrachlorodibenzo- p-dioxin in aryl hydrocarbon receptor-null mice. Arch Toxicol 79, 260-267, 2005.
86. Riedy M, Wang JY, Miller AP, Buckler A, Hall JM, et al.: Genomic organization of the UGT2b gene cluster on human chromosome 4q13. Pharmacogenetics 10, 251-260, 2000.
87. Bock KW, Gschaidmeier H, Heel H, Lehmkoster T, Munzel PA, et al.: AH receptor-controlled transcriptional regulation and function of rat and human UDP-glucuronosyltransferase isoforms. Adv Enzyme Regul 38, 207-222, 1998.
88. Chen S, Beaton D, Nguyen N, Senekeo-Effenberger K, Brace-Sinnokrak E, et al.: Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J Biol Chem 280, 37547-37557, 2005.
89. Finel M, Li X, Gardner-Stephen D, Bratton S, Mackenzie PI, and Radominska-Pandya A: Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity. J Pharmacol Exp Ther 315, 1143-1149, 2005.
90. Munzel PA, Bookjans G, Mehner G, Lehmkoster T, and Bock KW: Tissue-specific 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible expression of human UDP-glucuronosyltransferase UGT1A6. Arch Biochem Biophys 335, 205-210, 1996.
91. Munzel PA, Schmohl S, Buckler F, Jaehrling J, Raschko FT, et al.: Contribution of the Ah receptor to the phenolic antioxidant-mediated expression of human and rat UDP-glucuronosyltransferase UGT1A6 in Caco-2 and rat hepatoma 5L cells. Biochem Pharmacol 66, 841-847, 2003.
92. Munzel PA, Schmohl S, Heel H, Kalberer K, Bock-Hennig BS, et al.: Induction of human UDP glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. Drug Metab Dispos 27, 569-573, 1999.
93. Amakura Y, Tsutsumi T, Nakamura M, Kitagawa H, Fujino J, et al.: Activation of the aryl hydrocarbon receptor by some vegetable constituents determined using in vitro reporter gene assay. Biol Pharm Bull 26, 532-539, 2003.
94. Ashida H, Fukuda I, Yamashita T, and Kanazawa K: Flavones and flavonols at dietary levels inhibit a transformation of aryl hydrocarbon receptor induced by dioxin. FEBS Lett 476, 213-217, 2000.
95. Gradelet S, Astorg P, Leclerc J, Chevalier J, Vernevaut MF, et al.: Effects of canthaxanthin, astaxanthin, lycopene and lutein on liver xenobiotic-metabolizing enzymes in the rat. Xenobiotica 26, 49-63, 1996.
96. Jacobs MN and Lewis DF: Steroid hormone receptors and dietary ligands: a selected review. Proc Nutr Soc 61, 105-122, 2002.
97. Zhang S, Qin C, and Safe SH: Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect 111, 1877-1882, 2003.
98. Amakura Y, Tsutsumi T, Sasaki K, Yoshida T, and Maitani T: Screening of the inhibitory effect of vegetable constituents on the aryl hydrocarbon receptor-mediated activity induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biol Pharm Bull 26, 1754-1760, 2003.
99. Ciolino HP and Yeh GC: Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56, 760-767, 1999.
100. Fukuda I, Sakane I, Yabushita Y, Sawamura S, Kanazawa K, et al.: Black tea extract suppresses transformation of aryl hydrocarbon receptor induced by dioxin. Biofactors 21, 367-369, 2004.
101. Palermo CM, Hernando JI, Dertinger SD, Kende AS, and Gasiewicz TA: Identification of potential aryl hydrocarbon receptor antagonists in green tea. Chem Res Toxicol 16, 865-872, 2003.
102. Williams SN, Shih H, Guenette DK, Brackney W, Denison MS, et al.: Comparative studies on the effects of green tea extracts and individual tea catechins on human CYP1A gene expression. Chem Biol Interact 128, 211-229, 2000.
103. Zhang L, Zheng W, and Jefcoate CR: Ah receptor regulation of mouse Cyp1B1 is additionally modulated by a second novel complex that forms at two AhR response elements. Toxicol Appl Pharmacol 192, 174-190, 2003.
104. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivet A, et al.: Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56, 784-790, 1999.
105. Ciolino HP, Daschner PJ, and Yeh GC: Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 58, 5707-5712, 1998.
106. Orans J, Teotico DG, and Redinbo MR: The nuclear xenobiotic receptor pregnane X receptor: recent insights and new challenges. Mol Endocrinol 19, 2891-2900, 2005.
107. Handschin C and Meyer UA: Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 433, 387-396, 2005.
108. Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T, et al:. The pregnane X receptor regulates gene expression in a ligand-and promoter-selective fashion. Mol Endocrinol 19, 1170-1180, 2005.
109. Sugatani J, Sueyoshi T, Negishi M, and Miwa M: Regulation of the human UGT1A1 gene by nuclear receptors constitutive active/androstane receptor, pregnane X receptor, and glucocorticoid receptor. Methods Enzymol 400, 92-104, 2005.
110. Jacobs MN, Nolan GT, and Hood SR: Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol 209, 123-133, 2005.
111. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, et al.: 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 42, 1430-1438, 2003.
112. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, et al.: The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292, 2329-2333, 2001.
113. Bock KW and Kohle C: UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects. Methods Enzymol 400, 57-75, 2005.
114. Gardner-Stephen D, Heydel JM, Goyal A, Lu Y, Xie W, et al.: Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab Dispos 32, 340-347, 2004.
115. Xie W, Yeuh MF, Radominska-Pandya A, Saini SP, Negishi Y, et al.: Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 100, 4150-4155, 2003.
116. Chen C, Staudinger JL, and Klaassen CD: Nuclear receptor, pregname X receptor, is required for induction of UDP-glucuronosyltranferases in mouse liver by pregnenolone-16 alpha-carbonitrile. Drug Metab Dispos 31, 908-915, 2003.
117. Lin JH and Wong BK: Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr Drug Metab 3, 623-646, 2002.
118. Menard C, Lamiable D, Vistelle R, Morin E, and Ratanasavanh D: Induction and inhibition of cicletanine metabolism in cultured hepatocytes and liver microsomes from rats. Fundam Clin Pharmacol 14, 509-518, 2000.
119. Shelby MK and Klaassen CD: Induction of rat UDP-glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways. Drug Metab Dispos 34, 1772-1778, 2006.
120. Tukey RH, Pendurthi UR, Nguyen NT, Green MD, and Tephly TR: Cloning and characterization of rabbit liver UDP-glucuronosyltransferase cDNAs. Developmental and inducible expression of 4-hydroxybiphenyl UGT2B13. J Biol Chem 268, 15260-15266, 1993.
121. Moi P, Chan K, Asunis I, Cao A, and Kan YW: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 91, 9926-9930, 1994.
122. Venugopal R and Jaiswal AK: Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. Oncogene 17, 3145-3156, 1998.
123. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, et al.: Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 99, 11908-11913, 2002.
124. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, et al.: Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24, 7130-7139, 2004.
125. McMahon M, Itoh K, Yamamoto M, and Hayes JD: Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 278, 21592-21600, 2003.
126. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, et al.: Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. J Biol Chem 280, 30091-30099, 2005.
127. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, et al.: Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13, 76-86, 1999.
128. Ben-Dor A, Steiner M, Gheber L, Danilenko M, Dubi N, et al.: Carotenoids activate the antioxidant response element transcription system. Mol Cancer Ther 4, 177-186, 2005.
129. Nakamura Y, Yoshida C, Murakami A, Ohigashi H, Osawa T, et al.: Zerumbone, a tropical ginger sesquiterpene, activates phase II drug metabolizing enzymes. FEBS Lett 572, 245-250, 2004.
130. Wu CC, Hsu MC, Hsieh CW, Lin JB, Lai PH, et al.: Upregulation of heme oxygenase-1 by Epigallocatechin-3-gallate via the phosphatidylinositol 3-kinase/Akt and ERK pathways. Life Sci 78, 2889-2897, 2006.
131. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, et al.: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236, 313-322, 1997.
132. Nguyen T, Sherratt PJ, and Pickett CB: Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol 43, 233-260, 2003.
133. Katsuoka F, Motohashi H, Ishii T, Aburatani H, Engel JD, et al.: Genetic evidence that small maf proteins are essential for the activation of antioxidant response element-dependent genes. Mol Cell Biol 25, 8044-8051, 2005.
134. Chan K and Kan YW: Nrf2 is essential for protection against acute pulmonary injury in mice. Proc Natl Acad Sci USA 96, 12731-12736, 1999.
135. Chanas SA, Jiang Q, McMahon M, McWalter GK, McLellan LI, et al.: Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem J 365, 405-416, 2002.
136. McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, et al.: The cap'n'collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res 61, 3299-3307, 2001.
137. McWalter GK, Higgins LG, McLellan LI, Henderson CJ, Song L, et al.: Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. J Nutr 134, 3499S-3506S, 2004.
138. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, et al.: Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98, 3410-3415, 2001.
139. Nguyen T, Sherratt PJ, Huang HC, Yang CS, and Pickett CB: Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element: degradation of Nrf2 by the 26 S proteasome. J Biol Chem 278, 4536-4541, 2003.
140. Owuor ED and Kong AN: Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol 64, 765-770, 2002.
141. Huang HC, Nguyen T, and Pickett CB: Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 277, 42769-42774, 2002.
142. Rushworth SA, Ogborne RM, Charalambos CA, and O'Connell MA: Role of protein kinase C delta in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. Biochem Biophys Res Commun 341, 1007-1016, 2006.
143. Bloom DA and Jaiswal AK: Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem 278, 44675-44682, 2003.
144. Kim SO, Kundu JK, Shin YK, Park JH, Cho MH, et al.: [6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappaB in phorbol ester-stimulated mouse skin. Oncogene 24, 2558-2567, 2005.
145. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71, 1397-1421, 2006.
146. Balogun E, Hoque M, Gong P, Killeen E, Green CJ, et al.: Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 371, 887-895, 2003.
147. Ishikawa Y and Kitamura M: Anti-apoptotic effect of quercetin: intervention in the JNK- and ERK-mediated apoptotic pathways. Kidney Int 58, 1078-1087, 2000.
148. Lin JK, Chen YC, Huang YT, and Lin-Shiau SY: Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J Cell Biochem Suppl 28-29, 39-48, 1997.
149. Liu JY, Lin SJ, and Lin JK: Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 14, 857-861, 1993.
150. Salh B, Assi K, Templeman V, Parhar K, Owen D, et al.: Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 285, G235-G243, 2003.
151. Chen C, Yu R, Owuor ED, and Kong AN: Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res 23, 605-612, 2000.
152. Dong Z, Ma W, Huang C, and Yang CS: Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res 57, 4414-4419, 1997.
153. Kim HS, Kim MH, Jeong M, Hwang YS, Lim SH, et al.: EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res 24, 747-753, 2004.
154. Maeda-Yamamoto M, Suzuki N, Sawai Y, Miyase T, Sano M, et al.: Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells. J Agric Food Chem 51, 1858-1863, 2003.
155. Masuda M, Suzui M, and Weinstein IB: Effects of epigallocatechin-3- gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 7, 4220-4229, 2001.
156. Pianetti S, Guo S, Kavanagh KT, and Sonenshein GE: Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res 62, 652-655, 2002.
157. Sah JF, Balasubramanian S, Eckert RL, and Rorke EA: Epigallocatechin-3- gallate inhibits epidermal growth factor receptor signaling pathway, evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem 279, 12755-12762, 2004.
158. Wu BT, Hung PF, Chen HC, Huang RN, Chang HH, et al.: The apoptotic effect of green tea (-)-epigallocatechin gallate on 3T3-L1 preadipocytes depends on the Cdk2 pathway. J Agric Food Chem 53, 5695-5701, 2005.
159. Hou Z, Lambert JD, Chin KV, and Yang CS: Effects of tea polyphenols on signal transduction pathways related to cancer chemoprevention. Mutat Res 555, 3-19, 2004.
160. Shih CM, Lin H, Liang YC, Lee WS, Bi WF, et al.: Concentration-dependent differential effects of quercetin on rat aortic smooth muscle cells. Eur J Pharmacol 496, 41-48, 2004.
161. Wang X, Clubbs EA, and Bomser JA: Genistein modulates prostate epithelial cell proliferation via estrogen- and extracellular signal-regulated kinase-dependent pathways. J Nutr Biochem 17, 204-210, 2006.
162. Llorens F, Miro FA, Casanas A, Roher N, Garcia L, et al.: Unbalanced activation of ERK1/2 and MEK1/2 in apigenin-induced HeLa cell death. Exp Cell Res 299, 15-26, 2004.
163. Sarkar FH and Li Y: Cell signaling pathways altered by natural chemopreventive agents. Mutat Res 555, 53-64, 2004.
164. Lee JS and Surh YJ: Nrf2 as a novel molecular target for chemoprevention. Cancer Lett 224, 171-184, 2005.
165. Xu C, Yuan X, Pan Z, Shen G, Kim JH, et al.: Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol Cancer Ther 5, 1918-1926, 2006.
166. Nguyen T, Yang CS, and Pickett CB: The pathways and molecular mechanisms regulating NrG activation in response to chemical stress. Free Radic Biol Med 37, 433-441, 2004.
167. Shen G, Hebbar V, Nair S, Xu C, Li W, et al.: Regulation of Nrf2 transactivation domain activity. The differential effects of mitogen-activated protein kinase cascades and synergistic stimulatory effect of Raf and CREB-binding protein. J Biol Chem 279, 23052-23060, 2004.
168. Hayes JD and McMahon M: Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention. Cancer Lett 174, 103-113, 2001.
169. Kwak MK, Wakabayashi N, and Kensler TW: Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat Res 555, 133-148, 2004.
170. Metz RP and Ritter JK: Transcriptional activation of the UDP-glucuronosyltransferase 1A7 gene in rat liver by aryl hydrocarbon receptor ligands and oltipraz. J Biol Chem 273, 5607-5614, 1998.
171. Rushmore TH, Morton MR, and Pickett CB: The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 266, 11632-11639, 1991.
172. Wang M, Li YQ, Zhong N, Chen J, Xu XQ, et al.: [Induction of uridine 5′-diphosphate-glucuronosyltransferase gene expression by sulforaphane and its mechanism: experimental study in human colon cancel cells]. Zhonghua Yi Xue Za Zhi 85, 819-824, 2005.
173. Turgeon D, Carrier JS, Levesque E, Beatty BG, Belanger A, et al.: Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. J Mol Biol 295, 489-504, 2000.
174. Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, et al.: Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J Biol Chem 278, 32852-32860, 2003.
175. Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, et al.: The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem 278, 13975-13983, 2003.
176. Frank C, Gonzalez MM, Oinonen C, Dunlop TW, and Carlberg C: Characterization of DNA complexes formed by the nuclear receptor constitutive androstane receptor. J Biol Chem 278, 43299-43310, 2003.
177. Maglich JM, Watson J, McMillen PJ, Goodwin B, Willson TM, et al.: The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J Biol Chem 279, 19832-19838, 2004.
178. Ansell PJ, Lo SC, Newton LG, Espinosa-Nicholas C, Zhang DD, et al:. Repression of cancer protective genes by 17beta-estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor alpha. Mol Cell Endocrinol 243, 27-34, 2005.
179. Liu RH: Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 134, 3479S-3485S, 2004.
180. Talalay P and Fahey JW: Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. J Nutr 131, 3027S-3033S, 2001.
181. Jacobs DR Jr and Steffen LM: Nutrients, foods, and dietary patterns as exposures in research: a framework for food synergy. Am J Clin Nutr 78, 508S-513S, 2003.
182. Svehlikova V, Wang S, Jakubikova J, Williamson G, Mithen R, et al.: Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA1 in CaCo-2 cells. Carcinogenesis 25, 1629-1637, 2004.
183. Carlson DB and Perdew GH: A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J Biochem Mol Toxicol 16, 317-325, 2002.
184. Kato S, Sato T, Watanabe T, Takemasa S, Masuhiro Y, et al.: Function of nuclear sex hormone receptors in gene regulation. Cancer Chemother Pharmacol 56(Suppl 1). 4-9, 2005.
185. Matthews J and Gustafsson JA: Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl Recept Signal 4, e016, 2006.
186. Pocar P, Fischer B, Klonisch T, and Hombach-Klonisch S: Molecular interactions of the aryl hydrocarbon receptor and its biological and toxicological relevance for reproduction. Reproduction 129, 379-389, 2005.
187. Safe S: Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol Lett 120, 1-7, 2001.
188. Wormke M, Stoner M, Saville B, and Safe S: Crosstalk between estrogen receptor alpha and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes. FEBS Lett 478, 109-112, 2000.
189. Wormke M, Stoner M, Saville B, Walker K, Abdelrahim M, et al.: The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol Cell Biol 23, 1843-1855, 2003.
190. Cullinan SB, Gordan JD, Jin J, Harper JW, and Diehl JA: The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol 24, 8477-8486, 2004.
191. Buckley DB and Klaassen CD: Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab Dispos 35, 121-127, 2006.
192. Mercke Odeberg J, Andrade J, Holmberg K, Hoglund P, Malmqvist U, et al.: UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. Eur J Clin Pharmacol 62, 829-837, 2006.
193. Takeuchi T, Tsutsumi O, Nakamura N, Ikezuki Y, Takai Y, et al.: Gender difference in serum bisphenol A levels may be caused by liver UDP-glucuronosyltransferase activity in rats. Biochem Biophys Res Commun 325, 549-554, 2004.
194. Visser TJ, van Haasteren GA, Linkels E, Kaptei, E, van Toor H, et al.: Gender-specific changes in thyroid hormone-glucuronidating enzymes in rat liver during short-term fasting and long-term food restriction. Eur J Endocrinol 135, 489-497, 1996.
195. Diry M, Tomkiewicz C, Koehle C, Coumoul X, Bock KW, et al.: Activation of the dioxin/aryl hydrocarbon receptor (AhR) modulates cell plasticity through a JNK-dependent mechanism. Oncogene 25, 5570-5574, 2006.
196. Tan Z, Huang M, Puga A, and Xia Y. A critical role for MAP kinases in the control of Ah receptor complex activity. Toxicol Sci 82, 80-87, 2004.
197. Yim S, Oh M, Choi SM, and Park H: Inhibition of the MEK-1/p42 MAP kinase reduces aryl hydrocarbon receptor-DNA interactions. Biochem Biophys Res Commun 322, 9-16, 2004.
198. Bock KW and Kohle C: Coordinate regulation of drug metabolism by xenobiotic nuclear receptors: UGTs acting together with CYPs and glucuronide transporters. Drug Metab Rev 36, 595-615, 2004.
199. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, et al.: Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21, 689-700, 2006.
200. Court MH: Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400, 104-116, 2005.
201. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, et al.: Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275, 36164-36171, 2000.
202. Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, et al.: UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J Pharmacol Exp Ther 310, 656-665, 2004.
203. Plewka A, Kaminski M, and Plewka D: The influence of age and some inducers on UDP-glucuronyltransferase activity. Exp Gerontol 32, 305-313, 1997.
204. Strassburg CP, Vogel A, Kneip S, Tukey RH, and Manns MP: Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 50, 851-856, 2002.
205. Dalhoff K, Buus Jensen K, and Enghusen Poulsen H: Cancer and molecular biomarkers of phase 2. Methods Enzymol 400, 618-627, 2005.
206. Efferth T and Volm M: Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 107, 155-176, 2005.
207. Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, et al.: UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology 42, 448-457, 2005.
208. Lampe JW and Peterson S: Brassica, biotransformation and cancer risk: genetic polymorphisms alter the preventive effects of cruciferous vegetables. J Nutr 132, 2991-2994, 2002.
209. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, et al.: Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91, 249-258, 2005.
210. Peterson S, Bigler J, Horner NK, Potter JD, and Lampe JW: Cruciferae interact with the UGT1A1*28 polymorphism to determine serum bilirubin levels in humans. J Nutr 135, 1051-1055, 2005.
211. Adegoke OJ, Shu XO, Gao YT, Cai Q, Breyer J, et al.: Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer. Breast Cancer Res Treat 85, 239-245, 2004.
212. Duguay Y, McGrath M, Lepine J, Gagne JF, Hankinson SE, et al.: The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res 64, 1202-1207, 2004.
213. Guillemette C, Millikan RC, Newman B, and Housman DE: Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 60, 950-956, 2000.
214. Sparks R, Ulrich CM, Bigler J, Tworoger SS, Yasui Y, et al.: UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res 6, R488-498, 2004.
215. Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, and Ambudkar SV: Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm 3, 87-93, 2006.
216. Fenton JI, and Hord NG: Stage matters: choosing relevant model systems to address hypotheses in diet and cancer chemoprevention research. Carcinogenesis 27, 893-902, 2006.
217. Sun D, Lennernas H, Welage LS, Bamett JL, Landowski CP, et al.: Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 19, 1400-1416, 2002.
218. Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, et al.: Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos 31, 805-813, 2003.
219. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, et al.: Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 59, 5938-5946, 1999.
220. Cummings J, Zelcer N, Allen JD, Yao D, Boyd G, et al.: Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 67, 31-39, 2004.
221. Felton JS and Malfatti MA: What do diet-induced changes in phase I and II enzymes tell us about prevention from exposure to heterocyclic amines? J Nutr 136, 2683S-2684S, 2006.
222. Giuliani L, Ciotti M, Stoppacciaro A, Pasquini A, Silvestri I, et al.: UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep 13, 185-191, 2005.
223. Knize MG and Felton JS: Formation and human risk of carcinogenic heterocyclic amines formed from natural precursors in meat. Nutr Rev 63, 158-165, 2005.
224. Malfatti MA and Felton JS: Human UDP-glucuronosyltransferase 1A1 is the primary enzyme responsible for the N-glucuronidation of N-hydroxy-PhIP in vitro. Chem Res Toxicol 17, 1137-1144, 2004.
225. Malfatti MA, Wu RW, and Felton JS: The effect of UDP- glucuronosyltransferase 1A1 expression on the mutagenicity and metabolism of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in CHO cells. Mutat Res 570, 205-214, 2005.
226. Malfatti MA, Ubick EA, and Felton JS: The impact of glucuronidation on the bioactivation and DNA adduction of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo. Carcinogenesis 26, 2019-2028, 2005.
227. Tukey RH, Strassburg CP, and Mackenzie PI: Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 62, 446-450, 2002.
228. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, et al.: Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 8, R50, 2006.
229. Meyskens FL Jr and Szabo E: Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev 14, 1366-1369, 2005.
230. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, et al.: The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev 3, 155-160, 1994.
231. Taioli E, Garbers S, Bradlow HL, Carmella SG, Akerkar S, et al.: Effects of indole-3-carbinol on the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone in smokers. Cancer Epidemiol Biomarkers Prev 6, 517-522, 1997.
232. Vang O, Mehrota K, Georgellis A, and Andersen O: Effects of dietary broccoli on rat testicular xenobiotic metabolizing enzymes. Eur J Drug Metab Pharmacokinet 24, 353-359, 1999.
233. Humblot C, Lhoste E, Knasmuller S, Gloux K, Bruneau A, et al.: Protective effects of brussels sprouts, oligosaccharides and fermented milk towards 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)-induced genotoxicity in the human flora associated F344 rat: role of xenobiotic metabolising enzymes and intestinal microflora. J Chromatogr B Analyt Technol Biomed Life Sci 802, 231-237, 2004.
234. Kassie F, Rabot S, Uhl M, Huber W, Qin HM, et al.: Chemoprotective effects of garden cress (Lepidium sativum) and its constituents towards 2-amino-3-methyl-imidazo[4,5-f]quinoline (IQ)-induced genotoxic effects and colonic preneoplastic lesions. Carcinogenesis 23, 1155-1161, 2002.
235. Kassie F, Laky B, Gminski R, Mersch-Sundermann V, Scharf G, et al.: Effects of garden and water cress juices and their constituents, benzyl and phenethyl isothiocyanates, towards benzo(a)pyrene-induced DNA damage: a model study with the single cell gel electrophoresis/Hep G2 assay. Chem Biol Interact 142, 285-296, 2003.
236. Tepsuwan A, Kupradinun P, and Kusamran WR: Effect of Siamese cassia leaves on the activities of chemical carcinogen metabolizing enzymes and on mammary gland carcinogenesis in the rat. Mutat Res 428, 363-373, 1999.
237. Debersac P, Heydel JM, Amiot MJ, Goudonnet H, Artur Y, et al.: Induction of cytochrome P450 and/or detoxication enzymes by various extracts of rosemary: description of specific patterns. Food Chem Toxicol 39, 907-918, 2001.
238. Teyssier C, Amiot MJ, Mondy N, Auger J, Kahane R, et al.: Effect of onion consumption by rats on hepatic drug-metabolizing enzymes. Food Chem Toxicol 39, 981-987, 2001.
239. Le Bon AM, Vernevaut MF, Guenot L, Kahane R, Auger J, et al.: Effects of garlic powders with varying alliin contents on hepatic drug metabolizing enzymes in rats. J Agric Food Chem 51, 7617-7623, 2003.
240. Elegbede JA, Maltzman TH, Elson CE, and Gould MN: Effects of anticarcinogenic monoterpenes on phase II hepatic metabolizing enzymes. Carcinogenesis 14, 1221-1223, 1993.
241. Siess MH, Guillermic M, Le Bon AM, and Suschetet M: Induction of monooxygenase and transferase activities in rat by dietary administration of flavonoids. Xenobiotica 19, 1379-1386, 1989.
242. Siess MH, Mas JP, Canivenc-Lavier MC, and Suschetet M: Time course of induction of rat hepatic drug-metabolizing enzyme activities following dietary administration of flavonoids. J Toxicol Environ Health 49, 481-496, 1996.
243. Shertzer HG and Sainsbury M: Chemoprotective and hepatic enzyme induction properties of indole and indenoindole antioxidants in rats. Food Chem Toxicol 29, 391-400, 1991.
244. Ahn D, Putt D, Kresty L, Stoner GD, Fromm D, et al.: The effects of dietary ellagic acid on rat hepatic and esophageal mucosal cytochromes P450 and phase II enzymes. Carcinogenesis 17, 821-828, 1996.
245. Szaefer H, Cichocki M, Brauze D, and Baer-Dubowska W: Alteration in phase I and II enzyme activities and polycyclic aromatic hydrocarbons-DNA adduct formation by plant phenolics in mouse epidermis. Nutr Cancer 48, 70-77, 2004.
246. Hebbar V, Shen G, Hu R, Kim BR, Chen C, et al.: Toxicogenomics of resveratrol in rat liver. Life Sci 76, 2299-2314, 2005.
247. Ghosh B, Sardar S, Roy K, and Chatterjee M: Role of beta-carotene on the changes in activity patterns and levels of biotransforming enzymes in transplantable murine lymphoma. Cancer Lett 90, 191-197, 1995.
248. Haberkorn V, Heydel JM, Mounie J, Artur Y, and Goudonnet H: Influence of vitamin A status on the regulation of uridine (5′-)diphosphate- glucuronosyltransferase (UGT) 1A1 and UGT1A6 expression by L-triiodothyronine. Br J Nutr 85, 289-297, 2001.
249. Haberkom V, Heydel JM, Mounie J, Artur Y, and Goudonnet H: Vitamin A modulates the effects of thyroid hormone on UDP-glucuronosyltransferase expression and activity in rat liver. Mol Cell Endocrinol 190, 167-175, 2002.
250. Haberkorn V, Oziol L, and Goudonnet H: 9-cis-Retinoic acid regulation of four UGT isoforms in hepatocytes from rats with various thyroid states. Pharm Res 20, 1568-1573, 2003.
251. Lhoste EF, Gloux K, De Waziers I, Garrido S, Lory S, et al.: The activities of several detoxication enzymes are differentially induced by juices of garden cress, water cress and mustard in human HepG2 cells. Chem Biol Interact 150, 211-219, 2004.
252. Harrington WR, Sengupta S, and Katzenellenbogen BS: Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology 147, 3843-3850, 2006.
253. Basten GP, Bao Y, Williamson G: Sulforaphane and its glutathione conjugate but not sulforaphane nitrile induce UDP-glucuronosyl transferase (UGT1A1) and glutathione transferase (GSTA1) in cultured cells. Carcinogenesis 23, 1399-1404, 2002.
254. Bacon JR, Williamson G, Garner RC, Lappin G, Langouet S, et al.: Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human HepG2 cells and hepatocytes. Carcinogenesis 24, 1903-1911, 2003.
255. Yokoi T, Narita M, Nagai E, Hagiwara H, Aburada M, et al.: Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate. Jpn J Cancer Res 86, 985-989, 1995.
256. Chen W and Bowden GT: Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes. Oncogene 18, 7469-7476, 1999.
257. Chen CC, Chow MP, Huang WC, Lin YC, and Chang YJ: Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappaB: structure-activity relationships. Mol Pharmacol 66, 683-693, 2004.
258. Ciolino HP, Daschner PJ, and Yeh GC: Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem J 340(Pt 3), 715-722, 1999.
259. Liu DY, Zhu HJ, Zheng YF, and Zhu XQ: [Kaempferol activates human steroid and xenobiotic receptor-mediated cytochrome P450 3A4 transcription]. Zhejiang Da Xue Xue Bao Yi Xue Ban 35, 14-17, 2006.
260. O'Prey J, Brown J, Fleming J, and Harrison PR: Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells. Biochem Pharmacol 66, 2075-2088, 2003.
261. Chen C and Kong AN: Dietary chemopreventive compounds and ARE/EpRE signaling. Free Radic Biol Med 36, 1505-1516, 2004.
262. Liu DY, Yang M, Zhu HJ, Zheng YF, and Zhu XQ: [Human pregnane X receptor-mediated transcriptional regulation of cytochrome P450 3A4 by some phytochemicals]. Zhejiang Da Xue Xue Bao Yi Xue Ban 35, 8-13, 2006.
263. Ruiz PA and Haller D: Functional diversity of flavonoids in the inhibition of the proinflammatory NF-kappaB, IRF, and Akt signaling pathways in murine intestinal epithelial cells. J Nutr 136, 664-671, 2006.
264. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, et al.: Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 279, 8919-8929, 2004.
265. Ciolino HP and Yeh GC: The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. Br J Cancer 79, 1340-1346, 1999.
266. Chan HY, Wang H, and Leung LK: The red clover (Trifolium pratense) isoflavone biochanin A modulates the biotransformation pathways of 7,12-dimethylbenz[a]anthracene. Br J Nutr 90, 87-92, 2003.
267. Han EH, Kim JY, and Jeong HG: Effect of biochanin A on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Arch Pharm Res 29, 570-576, 2006.
268. Chaudhary LR and Hruska KA: Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem 89, 1-5, 2003.
269. Chen L, Mohr SN, and Yang CS: Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers. Clin Pharmacol Ther 60, 651-660, 1996.
270. Chen YR and Tan TH: Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17, 173-178, 1998.
271. Ciolino HP, Daschner PJ, Wang TT, and Yeh GC: Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Biochem Pharmacol 56, 197-206, 1998.
272. Kim JH, Xu C, Keum YS, Reddy B, Conney A, et al.: Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 27, 475-482, 2006.
273. Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, and Dunn FW: Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Lett 116, 197-203, 1997.
274. Rinaldi AL, Morse MA, Fields HW, Rothas DA, Pei P, et al.: Curcumin activates the aryl hydrocarbon receptor yet significantly inhibits (-)-benzo(a)pyrene-7R-trans-7,8-dihydrodiol bioactivation in oral squamous cell carcinoma cells and oral mucosa. Cancer Res 62, 5451-5456, 2002.
275. Van Dross R, Xue Y, Knudson A, and Pelting JC: The chemopreventive bioflavonoid apigenin modulates signal transduction pathways in keratinocyte and colon carcinoma cell lines. J Nutr 133, 3800S-3804S, 2003.
276. Alkhalaf M and Jaffal S: Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: novel cellular mechanisms involving the ERKs/p53 cascade. Free Radic Biol Med 41, 318-325, 2006.
277. Atten MJ, Attar BM, Milson T, and Holian O: Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem Pharmacol 62, 1423-1432, 2001.
278. Chen CY, Jang JH, Li MH, and Surh YJ: Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun 331, 993-1000, 2005.
279. Kaneider NC, Mosheimer B, Reinisch N, Patsch JR, and Wiedermann CJ: Inhibition of thrombin-induced signaling by resveratrol and quercetin: effects on adenosine nucleotide metabolism in endothelial cells and platelet-neutrophil interactions. Thromb Res 114, 185-194, 2004.
280. Kundu JK and Surh YJ: Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat Res 555, 65-80, 2004.
281. Kutuk O, Poli G, and Basaga H: Resveratrol protects against 4-hydroxynonenal-induced apoptosis by blocking JNK and c-JUN/AP-1 signaling. Toxicol Sci 90, 120-132, 2006.
282. Niles RM: Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat Res 555, 81-96, 2004.
283. Olson ER, Naugle JE, Zhang X, Bomser JA, and Meszaros JG: Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol 288, H1131-1138, 2005.
284. She QB, Bode AM, Ma WY, Chen NY, and Dong Z: Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases andp38 kinase. Cancer Res 61, 1604-1610.
285. She QB, Huang C, Zhang Y, and Dong Z: Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinog 33, 244-250, 2002.
286. Slater SJ, Seiz JL, Cook AC, Stagliano BA, and Buzas CJ: Inhibition of protein kinase C by resveratrol. Biochim Biophys Acta 1637, 59-69, 2003.
287. Stewart JR and O'Brian CA: Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest New Drugs 22, 107-117, 2004.
288. Stewart JR, Ward NE, Ioannides CG, and O'Brian CA: Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry 38, 13244-13251, 1999.
289. Woo JH, Lim JH, Kim YH, Suh SI, Min DS, et al.: Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 23, 1845-1853, 2004.
290. Yu R, Hebbar V, Kim DW, Mandlekar S, Pezzuto JM, et al.: Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol Pharmacol 60, 217-224, 2001.
291. Zamin LL, Dillenburg -Pilla P, Argenta-Comiran R, Horn AP, Simao F, et al.: Protective effect of resveratrol against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of PI3-K pathway. Neurobiol Dis 24, 170-182, 2006.
292. Aggarwal BB and Ichikawa H: Molecular targets and anticancer portential of indole-3-carbinol and its derivatives. Cell Cycle 4, 1201-1215, 2005.
293. Chinni SR and Sarkar FH: Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 8, 1228-1236, 2002.
294. Howells LM, Gallacher-Horley B, Houghton CE, Manson MM, and Hudson EA: Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line. Mol Cancer Ther 1, 1161-1172, 2002.
295. Li Y, Li X, and Sarkar FH: Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J Nutr 133, 1011-1019, 2003.
296. Rahman KM, Li Y, and Sarkar FH: Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr Cancer 48, 84-94, 2004.
297. Duraj J, Zazrivcova K, Bodo J, Sulikova M, and Sedlak J: Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma 52, 273-279, 2005.
298. Gouedard C, Barouki R, and Morel Y: Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol Cell Biol 24, 5209-5222, 2004.
299. Perez-Vizcaino F, Duarte J, and Andriantsitohaina R: Endothelial function and cardiovascular disease: effects of quercetin and wine polyphenols. Free Radic Res 40, 1054-1065, 2006.
300. Spencer JP, Rice-Evans C, and Williams RJ: Modulation of pro-survival Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and its in vivo metabolites underlie their action on neuronal viability. J Biol Chem 278, 34783-34793, 2003.
301. Huang X, Chen S, Xu L, Liu Y, Deb DK, et al.: Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res 65, 3470-3478, 2005.
302. Li Y and Sarkar FH: Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8, 2369-2377, 2002.
303. Wang J, Eltoum IE, and Lamartiniere CA: Genistein alters growth factor signaling in transgenic prostate model (TRAMP). Mol Cell Endocrinol 219, 171-180, 2004.
304. Acevedo-Duncan, M, Russell C, Patel S, and Patel R: Aloe-emodin modulates PKC isozymes, inhibits proliferation, and induces apoptosis in U-373MG glioma cells. Int Immunopharmacol 4, 1775-1784, 2004.
305. Huang Q, Shen HM, and Ong CN: Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem Pharmacol 68, 361-371, 2004.
306. Kim MS, Park MJ, Kim SJ, Lee CH, Yoo H, et al.: Emodin suppresses hyaluronic acid-induced MMP-9 secretion and invasion of glioma cells. Int J Oncol 27, 839-846, 2005.
307. Lee HZ, Hsu SL, Liu MC, and Wu CH: Effects and mechanisms of aloe-emodin on cell death in human lung squamous cell carcinoma. Eur J Pharmacol 431, 287-295, 2001.
308. Mijatovic S, Maksimovic-Ivanic D, Radovic J, Miljkovic D, Kaludjerovic GN, et al.: Aloe emodin decreases the ERK-dependent anticancer activity of cisplatin. Cell Mol Life Sci 62, 1275-1282, 2005.
309. Su YT, Chang HL, Shyue SK, and Hsu SL: Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol 70, 229-241, 2005.
310. Zhou X, Song B, Jin L, Hu D, Diao C, et al.: Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb. Bioorg Med Chem Lett 16, 563-568, 2006.
311. Ikeda Y, Murakami A, and Ohigashi H: Ursolic acid promotes the release of macrophage migration inhibitory factor via ERK2 activation in resting mouse macrophages. Biochem Pharmacol 70, 1497-1505, 2005.
312. Subbaramaiah K, Michaluart P, Sporn MB, and Dannenberg AJ: Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res 60, 2399-2404, 2000.
313. Shigeoka Y, Igishi T, Matsumoto S, Nakanishi H, Kodani M, et al.: Sulindac sulfide and caffeic acid phenethyl ester suppress the motility of lung adenocarcinoma cells promoted by transforming growth factor-beta through Akt inhibition. J Cancer Res Clin Oncol 130, 146-152, 2004.
314. Watabe M, Hishikawa K, Takayanagi A, Shimizu N, and Nakaki T: Caffeic acid phenethyl ester induces apoptosis by inhibition of NFkappaB and activation of Fas in human breast cancer MCF-7 cells. J Biol Chem 279, 6017-6026, 2004.
315. Zheng ZS, Xue GZ, Grunberger D, and Prystowsky JH: Caffeic acid phenethyl ester inhibits proliferation of human keratinocytes and interferes with the EGF regulation of ornithine decarboxylase. Oncol Res 7, 445-452, 1995.
316. Hu R, Khor TO, Shen G, Jeong WS, Hebbar V, et al.: Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis 27, 2038-2046, 2006.
317. Keum YS, Owuor ED, Kim BR, Hu R, and Kong AN: Involvement of Nrf2 and JNK1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent phenethyl isothiocyanate (PEITC). Pharm Res 20, 1351-1356, 2003.
318. Yu R, Lei W, Mandlekar S, Weber MJ, Der CJ, et al.: Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J Biol Chem 274, 27545-27552, 1999.
319. Yu R, Mandlekar S, Lei W, Fahl WE, Tan TH, et al.: p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J Biol Chem 275, 2322-2327, 2000.
320. Liagre B, Bertrand J, Leger DY, and Beneytout JL: Diosgenin, a plant steroid, induces apoptosis in COX-2 deficient K562 cells with activation of the p38 MAP kinase signalling and inhibition of NF-kappaB binding. Int J Mol Med 16, 1095-1101, 2005.
321. Shishodia S and Aggarwal BB: Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I kappa B kinase activation and NF-kappa B-regulated gene expression. Oncogene 25, 1463-1473, 2006.
322. Jakubikova J, Sedlak J, Mithen R, and Bao Y: Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem Pharmacol 69, 1543-1552, 2005.
323. Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS, et al.: Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene 23, 5594-5606, 2004.
324. Alsayed Y, Uddin S, Mahmud N, Lekmine F, Kalvakolanu DV, et al.: Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 276, 4012-4019, 2001.
325. Bost F, Caron L, Marchetti I, Dani C, Le Marchand-Brustel Y, et al.: Retinoic acid activation of the ERK pathway is required for embryonic stem cell commitment into the adipocyte lineage. Biochem J 361, 621-627, 2002.
326. Fisher GJ, Talwar HS, Lin J, Lin P, McPhillips F, et al.: Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. J Clin Invest 101, 1432-1440, 1998.
327. Gianni M, Bauer A, Garattini E, Chambon P, and Rochette-Egly C: Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation. EMBO J 21, 3760-3769, 2002.
328. Kanungo J, Potapova I, Malbon CC, and Wang H: MEKK4 mediates differentiation in response to retinoic acid via activation of c-Jun N-terminal kinase in rat embryonal carcinoma P19 cells. J Biol Chem 275, 24032-24039, 2000.
329. Sah JF, Eckert RL, Chandraratna RA, and Rorke EA: Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation. J Biol Chem 277, 9728-9735.
330. Singh US, Pan J, Kao YL, Joshi S, Young KL, et al.: Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J Biol Chem 278, 391-399, 2003.
331. Wang H, Ikeda S, Kanno S, Guang LM, Ohnishi M, et al.: Activation of c-Jun amino-terminal kinase is required for retinoic acid-induced neural differentiation of P19 embryonal carcinoma cells. FEBS Lett 503, 91-96, 2001.
332. Xu Q, Konta T, Furusu A, Nakayama K, Lucio-Cazana J, et al.: Transcriptional induction of mitogen-activated protein kinase phosphatase 1 by retinoids. Selective roles of nuclear receptors and contribution to the antiapoptotic effect. J Biol Chem 277, 41693-41700, 2002.
333. Yen A, Roberson MS, Varvayanis S, and Lee AT: Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 58, 3163-3172, 1998.
334. Gong P, Hu B, and Cederbaum AI: Diallyl sulfide induces heme oxygenase-1 through MAPK pathway. Arch Biochem Biophys 432, 252-260, 2004.
335. Knowles LM and Milner JA: Diallyl disulfide induces ERK phosphorylation and alters gene expression profiles in human colon tumor cells. J Nutr 133, 2901-2906, 2003.
336. Ruhl R: Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta 1740, 162-169, 2005.
337. Xiao D, Choi S, Lee YJ, and Singh SV: Role of mitogen-activated protein kinases in phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells. Mol Carcinog 43, 130-140, 2005.
338. Yu R, Jiao JJ, Duh JL, Tan TH, and Kong AN: Phenethyl isothiocyanate, a natural chemopreventive agent, activates c-Jun N-terminal kinase 1. Cancer Res 56, 2954-2959, 1996.
339. Chainy GB, Manna SK, Chaturvedi MM, and Aggarwal BB: Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB, AP-1, JNK, MAPKK and apoptosis. Oncogene 19, 2943-2950, 2000.